|
KMID : 0191120150300050612
|
|
Journal of Korean Medical Science
2015 Volume.30 No. 5 p.612 ~ p.616
|
|
|
The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
|
|
Kwon Hyo-Jin
Lee Soo-Young
Kim Ki-Hwan
Kim Dong-Soo
Cha Sung-Ho
Jo Dae-Sun
Kang Jin-Han
|
|
|
Abstract
|
|
|
|
Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the open-label, prospective cohort study to assess the immunogenicity and safety of this vaccine. Ninety subjects were enrolled, and LAJEV in a 2-dose primary series was given with a 12-month interval. Neutralizing antibody titers were measured before and after each vaccination, and active monitoring for adverse events was performed. After the first dose, 91.1% of subjects had seroprotection with a geometric mean titer (GMT) of 40.9. Seroprotection rate after the second dose was 97%, and GMT showed an increase of 6.5-fold. Most adverse events following immunization were self-limited, and no serious adverse events were reported until 42 days after each dose. The 2-dose administration of LAJEV in the primary immunization schedule appeared to be highly immunogenic and safe.
|
|
|
KEYWORD
|
|
|
Live Attenuated Japanese Encephalitis Vaccine, Immunogenicity, Safety, Children, Clinical Trial
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|